FDA Investigates Potential Cancer Risk in CAR-T Therapy

Despite Concerns, Experts Believe Benefits of Treatment Outweigh Potential Risks

FDA is investigating whether CAR-T therapy, a cancer treatment, can cause lymphoma in rare cases.
CAR-T therapy involves genetically modifying a patient's T cells to attack cancer cells.
Since 2017, six CAR-T cell therapies have been approved by the FDA, all for the treatment of blood cancers, including lymphomas and some forms of leukemia.
FDA has received reports of T-cell malignancies, including lymphomas and leukemias, after treatment with CAR-T therapies.
Despite the investigation, experts in the field believe the benefits of CAR-T therapy outweigh the potential risks.